• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Lixte Biotechnology Holdings Inc.

    4/6/22 9:58:22 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LIXT alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    Lixte Biotechnology Holdings, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

     

    (Title of Class of Securities)

     

    539319 202

     

    (CUSIP Number)

     

    December 17, 2021

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
         
      ☒ Rule 13d-1(c)
         
      ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall not be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP NO. 539319 10 3   Page 2 of 5 Pages

     

      1.

    NAMES OF REPORTING PERSONS.

    Glenn Krinsky

         
      2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☐

    (b) ☒

         
      3. SEC USE ONLY
         
         
      4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5. SOLE VOTING POWER 1,474,998
         
    6. SHARED VOTING POWER  
         
    7. SOLE DISPOSITIVE POWER 1,474,998
         
    8. SHARED DISPOSITIVE POWER  

     

         
      9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON.

    1,474,998(1)

         
         
      10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ☐
           
           
      11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    10.73% (2)

         
      12.

    TYPE OF REPORTING PERSON

    IN

     

     

      (1) Consists of 1,333,333 shares owned of record by the John and Barbara Kovach 2015 Trust of which the Reporting person is the sole Trustee and has voting, dispositive and investment power
      (2) Based on 13,746,593 shares of Common Stock, outstanding as of March 11, 2022.

     

     

     

     

    CUSIP NO. 539319 10 3   Page 3 of 5 Pages

     

    Explanatory Note: On December 17, 2021, the Reporting Person was appointed as successor Trustee of the John and Barbara 2015 Trust.

     

    Item 1(a). Name of Issuer.

     

    The name of the issuer is Lixte Biotechnology Holdings, Inc. (the “Issuer”).

     

    Item 1(b). Address of Issuer’s Principal Executive Offices.

     

    The address of the Issuer’s principal executive office is 680 East Colorado Boulevard, Suite 180, Pasadena CA 91101.

     

    Item 2(a). Name of Person Filing.

     

    Glenn Krinsky

     

    Item 2(b). Address of Principal Business Office, or, if None, Residence.

     

    680 East Colorado Boulevard, Suite 180, Pasadena CA 91101

     

    Item 2(c). Citizenship.

     

    United States citizen.

     

    Item 2(d). Title of Class of Securities.

     

    The title of the class of securities to which this statement relates is the Common stock, $0.0001 par value per share.

     

    Item 2(e). CUSIP No.

     

    The CUSIP number is 539319-202.

     

    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b) or 13d-2(b), Check Whether the Person Filing is a:

     

    (a) ☐ Broker or dealer registered under Section 15 of the Act
         
    (b) ☐ Bank as defined in Section 3(a)(6) of the Act
         
    (c) ☐ Insurance Company as defined in Section 3(a)(19) of the Act
         
    (d) ☐ Investment Company registered under Section 8 of the Investment Company Act of 1940
         
    (e) ☐ Investment Adviser registered under section 203 of the Investment Advisers Act of 1940
         
    (f) ☐ Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see Rule 13d-1(b)(1)(ii)(F)
         
    (g) ☐ Parent Holding Company, in accordance with Rule 13d-1(b)(1)(ii)(G) (Note: See Item 7)
         
    (h) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(H).

     

     

     

     

    CUSIP NO. 539319 10 3   Page 4 of 5 Pages

     

    Item 4. Ownership.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover pages and is incorporated herein by reference.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not Applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10. Certifications.

     

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP NO. 539319 10 3   Page 5 of 5 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Dated: April 06, 2022
       
      /s/ GLENN KRINSKY
      Glenn Krinsky

     

     

     

    Get the next $LIXT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LIXT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LIXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Primus Guy Warren

    3 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    9/10/25 2:20:02 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Stazzone Peter

    4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    9/4/25 2:58:31 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Stazzone Peter

    3 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    9/4/25 1:53:27 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment

    Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology BOCA RATON, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT) a biotech company focused on advancing cancer treatments, today announced it has completed the acquisition of Liora Technologies Europe Ltd., a UK-based company pioneering electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora will become a wholly owned subsidiary of LIXTE. The acquisition includes Liora's proprietary flagship technology LiGHT Sys

    11/25/25 8:30:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3

    BOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT, LIXTW)), a clinical-stage pharmaceutical company advancing LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A), today announced that Geordan Pursglove, its chief executive officer, will present at the Spartan Capital Investor Conference 2025 in New York, on November 3, 2025, at 4 p.m. ET. Management will conduct one-on-one meetings with investors during the conference. The conference will be held at the Marriott Marquis Hotel, 1535 Broadway. To register or schedule a one-on-one meeting, please visit https://spartancapital.com/spartan-capital-inves

    10/29/25 8:00:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans

    Company underscores clinical execution and confirms advanced negotiations underway on acquisition of complementary oncology assets BOCA RATON, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT, LIXTW)), a clinical-stage pharmaceutical company advancing LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A), today outlined its fourth-quarter 2025 priorities and provided an update on its strategic business development and acquisition initiatives focused on oncology. "LIXTE is entering Q4 with clear operational goals and a disciplined approach to strategic expansion," said Geordan Pursglove, Chairman and Chief Exe

    10/16/25 8:00:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    SEC Filings

    View All

    Lixte Biotechnology Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)

    12/11/25 2:51:47 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lixte Biotechnology Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)

    11/25/25 5:00:24 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Lixte Biotechnology Holdings Inc.

    10-Q - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)

    11/12/25 4:26:01 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Bernards Rene bought $24,116 worth of shares (10,000 units at $2.41), increasing direct ownership by 67% to 25,000 units (SEC Form 4) (Amendment)

    4/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    10/5/23 8:39:03 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Van Der Baan Bastiaan Jeroen bought $28,000 worth of shares (10,000 units at $2.80), increasing direct ownership by 1,000% to 11,000 units (SEC Form 4)

    4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    10/5/23 8:36:30 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bernards Rene bought $24,116 worth of shares (10,000 units at $2.41), increasing direct ownership by 33% to 20,000 units (SEC Form 4)

    4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    10/4/23 6:10:01 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Leadership Updates

    Live Leadership Updates

    View All

    LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

    -- Company Relocates Corporate Headquarters to Boca Raton -- Boca Raton, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced that Lourdes Felix and Guy Primus have joined the Company's Board of Directors, and Peter Stazzone has been named Chief Financial Officer. The Company also announced that it has relocated its corporate headquarters to Boca Raton. The new board members succeed Bas van der Baan, who remains Chief Scientific Officer of LIXTE, and René Bernards, PhD, who has been n

    9/3/25 8:00:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

    PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced the appointment of Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO). Dr. Schellens brings to LIXTE more than 25 years of clinical experience as a medical oncologist, pharmacologist and clinical pharmacologist, including more than two decades developing and bringing new drugs to market. He assumes the CMO role at LIXTE effective August 1, 2024, succeeding James S. Miser, M.D., who is leaving the Company after serv

    6/3/24 8:30:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

    Biotechnology Veteran Bas van der Baan Brings Precision Oncology Expertise; Founder John S. Kovach Named Executive Chairman PASADENA, CA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, announced that Bas van der Baan has been named as President and Chief Executive Officer of the Company, and as Vice Chairman of the Board of Directors, effective as of September 26, 2023. He has been a member of LIXTE'S Board of Directors since June 2022. Mr. van der Baan succeeds John S. Kovach, M.D., 87, who founded the Company in 2005 a

    9/26/23 8:30:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Financials

    Live finance-specific insights

    View All

    LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment

    Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology BOCA RATON, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT) a biotech company focused on advancing cancer treatments, today announced it has completed the acquisition of Liora Technologies Europe Ltd., a UK-based company pioneering electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora will become a wholly owned subsidiary of LIXTE. The acquisition includes Liora's proprietary flagship technology LiGHT Sys

    11/25/25 8:30:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Lixte Biotechnology Holdings Inc.

    SC 13G - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)

    4/6/22 9:58:22 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Lixte Biotechnology Holdings Inc. (Amendment)

    SC 13G/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)

    4/6/22 9:59:12 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed

    SC 13G - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)

    3/3/21 7:45:27 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care